Latest News

STAT Plus: With new combination drug data, Exelixis takes another shot at prostate cancer treatment

In 2014, the Bay Area biotech company Exelixis (EXEL) tried to develop a drug for prostate cancer; its clinical trial ended in failure and nearly shut down the company. A second attempt has delivered better, tumor-shrinking results, according to data released Monday, while still leaving some important questions unanswered.

In an interim look at the ongoing study, a combination regimen consisting of Exelixis’ targeted cancer drug Cabometyx and Roche’s checkpoint inhibitor Tecentriq demonstrated a tumor response rate of 32%. The median duration of response was 8.3 months.

Continue to STAT Plus to read the full story…

Source link

Related posts

New Year, New You? Not So Fast…


A New Look at Familial Risk of Inflammatory Bowel Disease in the Ashkenazi Jewish Population


Study finding promises new perspectives for treatment of Type 2 endometrial cancer


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World